Ann Dermatol.  2013 Feb;25(1):28-35. 10.5021/ad.2013.25.1.28.

Clinical, Quality of Life, Patient Adherence, and Safety Outcomes of Short-Course (12 Weeks) Treatment with Cyclosporine in Patients with Severe Psoriasis (the Practice Study)

• Swimberghe S
• Ghislain P
• Daci E
• Allewaert
• Denhaerynck K
• Hermans C
• Pacheco C
• Vancayzeele S
• MacDonald
• Abraham I

• KMID: 2265968
• DOI: http://doi.org/10.5021/ad.2013.25.1.28

Abstract

BACKGROUND
Apart from clinical outcomes, the "real-world" outcomes of intermittent short-course cyclosporine treatment remain poorly documented.
OBJECTIVE
To evaluate various outcomes of short-course cyclosporine treatment for severe psoriasis; and to describe dermatologists' use of the Rule of Tens.
METHODS
A 12-week pharmacoepidemiological study; 112 evaluable patients recruited by 43 dermatologists.
RESULTS
The mean initial cyclosporine dose was 2.88+/-0.74 mg/kg/day. At 12 weeks, 64.3% of patients were continued beyond the study period at mean dose of 2.51+/-0.91 mg/kg/day. Percent body surface affected, Psoriasis Area Severity Index score, and patient and physician rating of psoriasis severity decreased significantly, while quality of life (QoL) improved significantly. Median patient satisfaction at 12 weeks was 85 (0~100 scale). Patient-reported non-adherence was 43.9% and 56.1%, respectively at both the time points (p=0.18). In modeling on logarithmized outcomes variables, living along was consistently the single most important (negative) determinant of therapeutic and patient outcomes. Safety and tolerance parameters were similar to the ones reported in the literature. Only 7.3% of physicians correctly identified the measures included in the Rule of Tens and the Rule's criterion for inferring severe psoriasis.
CONCLUSION
With adequate monitoring and patient adherence, cyclosporine treatment reduces the severity of severe psoriasis, improves QoL, and is appropriately tolerated; leading to high patient satisfaction. Social support is a key determinant of therapeutic and patient outcomes and patients living along may require clinical attention. The relevance of the Rule of Tens was not evident.

Keyword

Cyclosporine; Pharmacoepidemiology; Psoriasis; Treatment outcome

MeSH Terms

Cyclosporine
Humans
Patient Compliance
Patient Satisfaction
Pharmacoepidemiology
Psoriasis
Quality of Life
Transcutaneous Electric Nerve Stimulation
Treatment Outcome
Cyclosporine

Reference

1. Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009. 361:496–509.

2. Christophers E. Psoriasis--epidemiology and clinical spectrum. Clin Exp Dermatol. 2001. 26:314–320.

3. Krueger GG, Feldman SR, Camisa C, Duvic M, Elder JT, Gottlieb AB, et al. Two considerations for patients with psoriasis and their clinicians: what defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis? J Am Acad Dermatol. 2000. 43:281–285.

4. Griffiths CE, Dubertret L, Ellis CN, Finlay AY, Finzi AF, Ho VC, et al. Ciclosporin in psoriasis clinical practice: an international consensus statement. Br J Dermatol. 2004. 150:Suppl 67. 11–23.

5. Rapp SR, Feldman SR, Exum ML, Fleischer AB Jr, Reboussin DM. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol. 1999. 41:401–407.

6. Kirby B, Fortune DG, Bhushan M, Chalmers RJ, Griffiths CE. The Salford Psoriasis Index: an holistic measure of psoriasis severity. Br J Dermatol. 2000. 142:728–732.

7. Finlay AY. Psoriasis from the patient's point of view. Arch Dermatol. 2001. 137:352–353.

8. Krueger G, Koo J, Lebwohl M, Menter A, Stern RS, Rolstad T. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol. 2001. 137:280–284.

9. Zachariae R, Zachariae H, Blomqvist K, Davidsson S, Molin L, Mørk C, et al. Quality of life in 6497 Nordic patients with psoriasis. Br J Dermatol. 2002. 146:1006–1016.

10. Seidler EM, Kimball AB. Socioeconomic disability in psoriasis. Br J Dermatol. 2009. 161:1410–1412.

11. Smith CH, Barker JN. Psoriasis and its management. BMJ. 2006. 333:380–384.

12. Richards HL, Fortune DG, Griffiths CE, Main CJ. The contribution of perceptions of stigmatisation to disability in patients with psoriasis. J Psychosom Res. 2001. 50:11–15.

13. Vardy D, Besser A, Amir M, Gesthalter B, Biton A, Buskila D. Experiences of stigmatization play a role in mediating the impact of disease severity on quality of life in psoriasis patients. Br J Dermatol. 2002. 147:736–742.

14. Richards HL, Fortune DG, Griffiths CE. Adherence to treatment in patients with psoriasis. J Eur Acad Dermatol Venereol. 2006. 20:370–379.

15. Feldman SR, Horn EJ, Balkrishnan R, Basra MK, Finlay AY, McCoy D, et al. Psoriasis: improving adherence to topical therapy. J Am Acad Dermatol. 2008. 59:1009–1016.

16. Ali SM, Brodell RT, Balkrishnan R, Feldman SR. Poor adherence to treatments: a fundamental principle of dermatology. Arch Dermatol. 2007. 143:912–915.

17. Ho VC. The use of ciclosporin in psoriasis: a clinical review. Br J Dermatol. 2004. 150:Suppl 67. 1–10.

18. Finlay AY. Current severe psoriasis and the rule of tens. Br J Dermatol. 2005. 152:861–867.

19. Menter A, Griffiths CE. Current and future management of psoriasis. Lancet. 2007. 370:272–284.

20. Madan V, Griffiths CE. Systemic ciclosporin and tacrolimus in dermatology. Dermatol Ther. 2007. 20:239–250.

21. Warren RB, Griffiths CE. Systemic therapies for psoriasis: methotrexate, retinoids, and cyclosporine. Clin Dermatol. 2008. 26:438–447.

22. Rosmarin DM, Lebwohl M, Elewski BE, Gottlieb AB. National Psoriasis Foundation. Cyclosporine and psoriasis: 2008 National Psoriasis Foundation Consensus Conference. J Am Acad Dermatol. 2010. 62:838–853.

23. Ho VC, Griffiths CE, Albrecht G, Vanaclocha F, León-Dorantes G, Atakan N, et al. The PISCES Study Group. Intermittent short courses of cyclosporin (Neoral(R)) for psoriasis unresponsive to topical therapy: a 1-year multicentre, randomized study. Br J Dermatol. 1999. 141:283–291.

24. Ho VC, Griffiths CE, Berth-Jones J, Papp KA, Vanaclocha F, Dauden E, et al. Intermittent short courses of cyclosporine microemulsion for the long-term management of psoriasis: a 2-year cohort study. J Am Acad Dermatol. 2001. 44:643–651.

25. Touw CR, Hakkaart-Van Roijen L, Verboom P, Paul C, Rutten FF, Finlay AY. Quality of life and clinical outcome in psoriasis patients using intermittent cyclosporin. Br J Dermatol. 2001. 144:967–972.

26. Heydendael VM, Spuls PI, Opmeer BC, de Borgie CA, Reitsma JB, Goldschmidt WF, et al. Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. N Engl J Med. 2003. 349:658–665.

27. Salek MS, Finlay AY, Lewis JJ, Sumner MI. Quality of life improvement in treatment of psoriasis with intermittent short course cyclosporin (Neoral). Qual Life Res. 2004. 13:91–95.

28. Chaidemenos GC, Mourellou O, Avgoustinaki N, Papakonstantinou M, Karakatsanis G, Katsambas A. Intermittent vs. continuous 1-year cyclosporin use in chronic plaque psoriasis. J Eur Acad Dermatol Venereol. 2007. 21:1203–1208.

29. Flytström I, Stenberg B, Svensson A, Bergbrant IM. Methotrexate vs. ciclosporin in psoriasis: effectiveness, quality of life and safety. A randomized controlled trial. Br J Dermatol. 2008. 158:116–121.

30. Renzi C, Tabolli S, Picardi A, Abeni D, Puddu P, Braga M. Effects of patient satisfaction with care on health-related quality of life: a prospective study. J Eur Acad Dermatol Venereol. 2005. 19:712–718.